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The neurobiology of suicidal behaviour, which constitutes one of the most serious problems both in psychiatry and
general medical practice, still remains to a large degree unclear. As a result, scientists constantly look for new
opportunities of explaining the causes underlying suicidality. In order to elucidate the biological changes occurring
in the brains of the suicide victims, studies based on post-mortem brain tissue samples are increasingly being used.
These studies employ different research methods to provide an insight into abnormalities in brain functioning on
various levels, including gene and protein expression, neuroplasticity and neurotransmission, as well as many other
areas. The aim of this paper to summarize the available data on the post-mortem studies, to provide an overview of
main research directions and the most up-to-date findings, and to indicate the possibilities of further research in
this field.
Keywords: Autopsy, Biological Psychiatry, Depression, Genetics, Hypothalamic-pituitary-adrenal (HPA) axis, Neural
Plasticity, Neurotransmitter, ProteomicsIntroduction
Suicide is one of the leading causes of death globally for
all ages. Every year, nearly one million people die from
suicide according to WHO, 2013. It therefore constitutes
a serious medical and social problem, and as such calls
for profound and systematic research to enable a better
understanding of the underlying pathology, as well as
the development of new therapeutic approaches. Sui-
cides and suicide attempts are usually associated with
mental illness including affective or psychotic disorders
as well as alcohol and/or substance abuse disorders [1,2].
Suicide is therefore an important focus of neuropsychiatric
research. Among psychiatric disorders, mood disorders,
schizophrenia and alcoholism are most often co-morbid
with suicide [3]. A number of risk factors for suicidal
behaviour has been identified, including stress [4],
impulsive-aggressive behaviour [5], chronic disease [6]
and hopelessness [7]. On the other hand, protective fac-
tors such as a stable relationship, a well-established so-
cial network and a dependable financial situation [8,9]
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reproduction in any medium, provided the orcorrelates for suicide have been identified, the neuro-
biology of suicide remains less clear. The studies of bio-
logical abnormalities associated with suicidal behaviour,
performed in biomaterials such as blood cells, cerebro-
spinal fluid and plasma obtained from suicidal patients,
have shed some light on this matter. As a result, an in-
volvement of serotonergic [10-13], dopaminergic and
noradrenergic systems [14,15], as well as abnormalities
in the hypothalamic-pituitary-adrenocortical axis [14,16]
were proposed. However, it is not clear if, and to what ex-
tent, those observations reflect the pathomechanisms in
the brain. Here, the availability of well-characterized post-
mortem brain samples of suicide victims has proven very
useful for research. This article gives a description of the
nature of post-mortem studies, of the opportunities they
provide, but also of their limitations. Next, it summarizes
the results emerging from these studies and its role in en-
hancing our understanding of suicide. We have aimed at
providing the reader with an overview of primary studies
looking at genetics, proteomics, neurotransmitter systems,
cell-signaling, neural plasticity and neuroendocrinology,
that used specific and reproducible methods [17]. Overall,
we aimed at summarizing consistent results, already de-
scribed and evaluated by a number of different authors.
On the other hand, studies showing contradictory resultsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to better point out new research directions, such incon-
sistent studies have also been included in our review. Last
but not least, although we concentrate on the most up-
to-date findings, we also describe a number of the most
important older studies, which have provided the basis for
the more recent ones.
Review
Post-mortem studies in suicide victims
Post-mortem brain samples obtained from suicide victims
and controls offer many new opportunities to study mo-
lecular mechanisms underlying suicidal behaviour. In con-
trast to earlier studies based on peripheral tissues, research
enables a direct insight into the neurobiological abnormal-
ities associated with suicide. However, it is important to be
aware that those studies need to meet certain criteria [18].
To begin with, a positive opinion of the local ethical com-
mission is mandatory for every study involving the examin-
ation of human brain samples. Next, because the brain
tissue degrades very easily, the process of collecting samples
for post-mortem studies should be carried out with special
care. The collection of the samples should ideally take place
no longer than 48 hours after death. In order to establish
the quality of collected tissue and determine whether
it is adequate for measuring protein levels and gene
expression, pH of the samples and the RNA integrity
number should be determined. Since methyltransferase-
and acetyltransferase-activities measured in brain samples
were reported to be relatively preserved and independent of
storage duration or post-mortem interval Monoranu et al.
[19] proposed to use their levels as stability markers in epi-
genetic studies. On the other hand, an increased storage
period has been shown to influence tryptophan levels,
which led to the conclusion that the level of this amino acid
might indicate the level of protein degradation in the sam-
ple [20]. Next, it is very important to carefully examine the
samples for any neuropathological abnormalities. This can
be combined with dissecting particular regions of the brain,
so that the exact neuroanatomical location of examined
molecular processes can be taken into account. Since
many psychiatric patients have been on several medica-
tions, and a drug addiction is often associated with
suicidality, it is also advisable to obtain an accurate toxico-
logical screening of the samples. Alternatively, toxico-
logical tests can be performed using the blood of the
subjects. Last but not least, a “psychological autopsy”
should be obtained from the subjects’ families and friends,
including psychiatric diagnoses, physical disorders, child-
hood history, possibilities of early life trauma and history of
adverse life events. Nowadays, post-mortem brain collec-
tion programs [21] have minimized the difficulties resulting
from these prerequisites, readily offering samples collected
using standardized methods. Studies based on brain tissuehave been focusing different immunological and biochem-
ical mechanisms, as well as gene expression and brain cyto-
architecture. Below are presented the key topics of this
research in relation to suicidality.
Genetic studies
Looking at a possible role of various genetic factors in
suicidal behaviour can broaden our knowledge of differ-
ent neurobiological elements responsible for this path-
ology. A number of studies have focused on one or
several genes at a time, comparing suicide victims with
controls. This led to the identification of genetic predis-
posing factors, such as WFS1 [22,23] or p75NTR [24] as
well as many others. On the other hand, many re-
searchers proposed an involvement of a whole family of
genes or certain pathways rather than just single genes
in the pathology of different psychiatric disorders
[25,26]. For example, Must et al. [27] found common
variations in a group of genes located in the 4p locus to
be related to completed suicide in male individuals.
However, to confirm the biological relevance of these
studies, it is necessary to replicate the findings in similar
and comparable clinical samples with comprehensive
coverage of the variants at a particular candidate locus
[28]. To this end, genome-wide association studies and
mRNA expression studies can help to verify to the sig-
nificance of previous reports and distinguish biochem-
ical pathways and processes particularly important to
the pathophysiology of suicide. The association studies
provide a powerful tool for discovering the strongest
and most common links between different genes and
suicide. The expression studies enable a detailed de-
scription of gene expression patterns characteristic for
different brain regions. In order to obtain reliable re-
sults, it is crucial to match the groups of studied subjects
and controls according to age, sex, ethnic background and
post-mortem intervals. A promising approach for gene ex-
pression studies is the use of oligonucleotide microarrays
for the analysis of mRNA levels in the brain tissue. In
order to ensure high dependability of the final results,
several microarray RNA integrity indicators can be
used, such as noise (RawQ) or consistent β-actin and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
5'/3' signal ratios. However, there is some controversy in
relation to the idea of the housekeeping genes and, since
the levels of the mRNA for β-actin and GAPDH have
also been found to be dependent of cellular profiles and
activation, there is a need for finding new methods of
controlling the RNA integrity [29]. When analyzing the
whole genome, the researchers inevitably face the problem
of processing large amounts of complex information. It is
therefore important to use reliable tools to summarize and
functionally explore the collected data. Here, electronic
data bases, as well as gene ontology and enrichment
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is the implementation of sufficiently stringent significance
criteria to identify differentially expressed genes biologically
relevant to suicide. One of the commonly used tests is the
combination of an ANOVA and subsequent t-tests, also re-
ferred to as Fisher protected least significant difference
(LSD) test [28]. What is more, when running multiple tests
it is always important to confirm the statistical significance
using corresponding tools, for example the Bonferroni cor-
rection [30]. The analysis of gene ontology categories is
one of the possibilities to organize the collected data
and transparently present the role of the distinguished
genes. Sequeira et al. [28] looked at patterns of gene ex-
pression in the limbic system of suicide victims to identify
differentially expressed genes. The vast majority of ex-
pression changes were observed in the amygdala and
hippocampus. Amongst the most strongly overrepre-
sented genes where those involved in transcriptional
regulation and metabolism: APLP2, BACE1, SYT4, ADCY8,
GABRA1 and GABRB1. The identification of the adenyl-
ate cyclase 8 gene (ADCY8) confirms previous evidence
of a possible involvement of the adenyl cyclase (AC) sig-
naling system in the pathophysiology of suicide (see
below). Interestingly, the findings are paralleled by the
reports from animal studies: APLP2 knockout mice
present with a reduction in both density and num-
ber of docked vesicles at the active zone [31], while
SYT4 knockouts display reduced levels of anxiety and
depression-like behaviour [32]. Sequeira and colleagues
also approach a problem of a possible confounding effect
on the gene expression by psychoactive drugs.
Genetic studies offer a unique possibility of comparing
the effects of both long-term substance abuse (in sub-
jects with documented chronic dependence) and acute
substance exposure (in subjects without such history but
with positive toxicological screening) on gene expres-
sion. The same research group performed gene expres-
sion analyses in 17 cortical and subcortical brain
regions from suicide victims with and without major de-
pression and controls [33]. They observed the highest
number of suicide specific alterations in prefrontal cor-
tical areas and hippocampus (HIP). With the use of the
gene ontology analysis, alterations of synaptic neurotrans-
mission and intracellular signaling were revealed.
Among these, glutamatergic [34] and GABAergic re-
lated genes were globally altered. Thalmeier et al. [35] also
performed a classification of the differentially expressed
genes according to their biological function and statistical
analyses of the data, using post-mortem orbitofrontal
cortex of violent suicide victims and control subjects.
As a result, they found nine particularly interesting tran-
scripts (CDCA7L, CDH12, EFEMP1, MLC1, PCDHB5,
PTPRR, S100A13, SCN2B, and ZFP36). The subsequent
pathway analysis showed that the gene ontology categories'central nervous system development', 'homophilic cell ad-
hesion', 'regulation of cell proliferation' and 'transmission of
nerve impulse' were significantly enriched. In a re-ana-
lysis of a large set of Affymetrix Human Genome
U133A microarray data, Kim et al. [36] compared gene
expression levels between suicide completers vs. non-
suicide groups within two diagnostic groups, namely
bipolar disorder and schizophrenia. Among bipolar
samples, 13 genes and among schizophrenia samples, 70
genes were found to be differentially expressed.
According to real-time quantitative PCR data, PLSCR4
and EMX2 were significantly down-regulated in the
schizophrenia suicide completers, but not in patients with
bipolar disorder. One of the genes found to be up-
regulated in the bipolar group was gamma-amino butyric
acid A receptor, α5 subunit (GABRA5), which, similarly to
the finding of GABRA1 up-regulation by Sequeira et al.
[28], indicates a possible involvement of the GABAergic
neurotransmitter system in suicide. The authors concluded
that, since the overlap of genes among the two diagnostic
groups was small, a larger number of disorder-specific
genes was found. This suggests that disorder-specific path-
ways dominate over common pathways at the molecular
level. Sibille and colleagues [37] used DNA microarrays to
conduct a large-scale gene expression analysis in two re-
gions of the human prefrontal cortex obtained from post-
mortem matched groups of subjects with major depression
who died by suicide, and control subjects who died from
other causes and were free from psychiatric disorders. Al-
though the authors investigated molecular and cellular
pathways potentially involved in depression and suicidal be-
haviour, and tested several hypotheses of disease pathology
and of their putative molecular impact, including changes
in single genes, the existence of subgroups of patients or
disease subtypes, or the possibility of common biological
pathways being affected in the disease process, no evidence
for molecular differences that correlated with depression
and suicide was found. As a result, the authors hypothe-
sized that either the research methods they used were not
sensible enough, or the pathology characteristic for depres-
sion was localized in other brain areas and possibly rather
associated with post-transcriptional effects and/or changes
in protein levels or functions, than with altered transcrip-
tion in the prefrontal cortex (PFC) Table 1 provides an
overview of the genes possibly involved in suicide.
Proteomics
The analysis of proteome, defined as an entity of all pro-
teins of a cell, a tissue or an organism at a certain time
and under exact defined conditions [38] , can help identify
new suicide-associated proteins or protein modifications.
The proteome is by definition highly dynamic and vari-
able, i.e. easily influenced by a change in various intra-
and extracellular processes. Similarly, the variety of factors
Table 1 Genes possibly involved in suicide
Gene
symbol
Description Change Location Diagnosis Reference
A2M alpha-2-macroglobulin upregulation PFC SCH 35
ABCG2 ATP-binding cassette, sub-family G(WHITE),
member 2
upregulation PFC aSCH 35
ADCY8 adenylate cyclase 8 (brain) upregulation LS MD 27
ADRA2A adrenoceptor alpha 2A higher frequency of the
C1291G SNP
G upregulated 73, 115
ADRA2B adrenoceptor alpha 2B higher frequency of the
rs1018351 SNP
G NC 116
AGT angiotensinogen (serpin peptidase inhibitor,
clade A, member 8)
downregulation PFC SCH 35
AGXT2L1 alanine-glyoxylate aminotransferase 2-like 1 downregulation PFC SCH 35
AHCYL1 S-adenosylhomocysteine hydrolase-like 1 downregulation PFC SCH 35
ALDH1L1 aldehyde dehydrogenase 1 family, member L1 downregulation PFC SCH 35
APLP2 amyloid beta (A4) precursor-like protein 2 upregulation L MD 27
APOE Apolipoprotein E downregulation PFC SCH 35
APOLD1 apolipoprotein L domain containing 1 downregulation PFC SCH 35
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide downregulation PFC SCH 35
ATP1B2A ATPase, Na+/K+ transporting, beta 2 polypeptide downregulation PFC SCH 35
BACE1 beta-site APP-cleaving enzyme 1 upregulation LS MD 27
BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1 downregulation PFC SCH 35
BDNF brain-derived neurotrophic factor downregulatoin PFC, HIP NC 173, 174
C3 complement component 3 upregulation PFC SCH 35
CD74 CD74 molecule, major histocompatibility complex,
class II invariant chain
upregulation PFC SCH 35
CDCA7L cell division cycle associated 7-like not characterised PFC NC 34
CDH12 cadherin 12, type 2 (N-cadherin 2) not characterised PFC NC 34
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) downregulation PFC BD 35
CLDN10 claudin 10 downregulation PFC SCH 35





CRH corticotropin releasing hormone upregulation PFC SCH 35
CSF1R colony stimulating factor 1 receptor upregulation PFCS CH 35
CX3CR1 chemokine (C-X3-C motif) receptor 1 upregulation PFC SCH 35
DARPP-32 protein phosphatase 1, regulatory (inhibitor)
subunit 1B
downregulation PFC SCH 128
DDIT4 DNA-damage-inducible transcript 4 downregulation PFC SCH 35
DUSP6 dual specificity phosphatase 6 upregulation PFC SCH 35
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 downregulation PFC SCH 35
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 not characterised PFC NC 34
EIF5A eukaryotic translation initiation factor 5A downregulation PFC SCH 35
EMX2 empty spiracles homolog 2 (Drosophila) downregulation PFC SCH 34, 35
EMX2 empty spiracles homolog 2 (Drosophila) downregulation PFC BD 35
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) downregulation PFC SCH 35





FAM107A family with sequence similarity 107, member A downregulation PFC SCH 35
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Table 1 Genes possibly involved in suicide (Continued)
FGFR3 fibroblast growth factor receptor 3 (achondroplasia,
thanatophoric dwarfism)
downregulation PFC SCH 35
FXYD1 FXYD domain containing ion transport regulator 1
(phospholemman)
downregulation PFC SCH 35
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 upregulation LS MD 27
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 upregulation PFC BD 34, 35
GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 upregulation LS MD 27
GLUL glutamate-ammonia ligase (glutamine synthetase) downregulation PFC SCH 35
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 upregulation PFC SCH 35
HLA-DRA major histocompatibility complex, class II, DR alpha upregulation PFC SCH 35
HSPB1 heat shock 27 kDa protein 1 downregulation PFC SCH 35
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C,
G protein-coupled





ID4 inhibitor of DNA binding 4, dominant negative
helix-loop-helix protein
downregulation PFC SCH 36
IL17RB interleukin 17 receptor B downregulation PFC SCH 35
ITGB4 integrin, beta 4 downregulation PFC SCH 35
ITPKB inositol 1,4,5-trisphosphate 3-kinase B downregulation PFC SCH 35
LAPTM5 lysosomal associated multispanning
membrane protein 5
upregulation PFC SCH 35
LDLR low density lipoprotein receptor downregulation PFC BD 35
LOC645745 metallothionein 1H-like protein downregulation PFC SCH 35
lTrkB neurotrophic tyrosine kinase, receptor, type 2 downregulation PFC, HIP NC 171
METTL7A methyltransferase like 7A downregulation PFC SCH 35
MLC1 megalencephalic leukoencephalopathy with
subcortical cysts 1
downregulation PFC SCH 35
MLC1 megalencephalic leukoencephalopathy with
subcortical cysts 1
not characterised PFC NC 34
MT1E metallothionein 1E (functional) downregulation PFC SCH 35
MT1F metallothionein 1F (functional) downregulation PFC SCH 35
MT1G metallothionein 1G dcownregulation PFC SCH 35
MT1H metallothionein 1H downregulation PFC SCH 35
MT1M metallothionein 1M downregulation PFC SCH 35
MT1X metallothionein 1X downregulation PFC SCH 35
NAV2 neuron navigator downregulation PFC BD 35
NDRG2 NDRG family member 2 downregulation PFC SCH 35
NOTCH2 Notch homolog 2 (Drosophila) downregulation PFC SCH 35
NPY neuropeptide Y upregulation PFC SCH 35
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 downregulation PFC SCH 35
NTSR2 neurotensin receptor 2 downregulation PFC SCH 35
P2RY13 purinergic receptor P2Y, Gprotein coupled, 13 upregulation PFC SCH 35
p75NTR (NGFR) nerve growth factor receptor higher frequency of the missense
polymorphism (S205L)
G MD 23
PCDHB5 protocadherin beta 5 NC PFC NC 34
PLSCR4 phospholipid scramblase 4 downregulation PFC SCH 34, 35
PLSCR4 phospholipid scramblase 4 downregulation PFC BD 35
PPAP2B phosphatidic acid phosphatase type 2B downregulation PFC SCH 35
PRKCI protein kinase C, iota upregulated PFC NC 150
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PTPRR protein tyrosine phosphatase, receptor type, R downregulation PFC NC 34
RAB31 RAB31, member RAS oncogene family downregulation PFC SCH 35
RHOBTB34 Rho-related BTB domain containing 3 downregulation PFC SCH 35
S100A13 S100 calcium binding protein A13 not characterised PFC NC 34
SAT1 spermidine/spermine N1-acetyltransferase 1 downregulation, higher frequency
of the rs6526342 SNP
PFC MD 186, 187, 188,
189, 190, 192
SCN2B sodium channel, voltage-gated,
type II, beta subunit
not characterised PFC NC 34
SDC2 syndecan 2 (heparan sulfate proteoglycan 1,
cell surfaceassociated, fibroglycan)
downregulation PFC SCH 35
SDC4 syndecan 4 (amphiglycan, ryudocan) downregulation PFC SCH 35
SLC14A1 solute carrier family 14 (urea transporter), member 1
(Kidd blood group)
downregulation PFC SCH 35
SLC1A3 solute carrier family 1 (glial high affinity glutamate
transporter), member 3
downregulation PFC SCH 35
SLC25A23 solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 23
upregulation PFC SCH 35
SLC4A4 solute carrier family 4, sodium bicarbonate
cotransporter, member 4
downregulation PFC SCH 35
SLC6A3 solute carrier family 6 (neurotransmitter transporter,
dopamine), member 3
higher frequency of the
rs403636 SNP
G NC 116
SLC7A11 solute carrier family 7, (cationic amino acid
transporter, y+system) member 11
downregulation PFC SCH 35
SOX9 SRY (sex determining region Y)-box 9 downregulation PFC SCH 35
SPON1 spondin 1, extracellular matrix protein downregulation PFC SCH 35
STCH stress 70 protein chaperone,
microsome-associated, 60 kDa
upregulation PFC BD 35
SYT4 synaptotagmin IV upregulation LS MD 27 TIMP1
TIMP metallopeptidase inhibitor 1
downregulation PFC BD 35
TM4SF1 transmembrane 4 L six family member 1 downregulation PFC BD 35
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 upregulation PFC SCH 35
TP53BP2 tumor protein p53 binding protein, 2 downregulation PFC SCH 35
TPD52L1 tumor protein D52-like 1 downregulation PFC SCH 35
TPH2 tryptophan hydroxylase 2 higher frequeny of the
rs1386494 SNP
G NC 88
TRIM23 tripartite motif-containing 23 upregulation PFC BD 35
TUBB2B tubulin, beta 2B downregulation PFC SCH 35
TYROBP TYRO protein tyrosine kinase binding protein upregulation PFC SCH 35
VIL2 villin 2 (ezrin) downregulation PFCS CH 35
WFS1 Wolfram syndrome 1 (wolframin) higher frequency of the
611R/611R genotype
G NC 21, 22
ZFP36 ZFP36 ring finger protein not characterised PFC NC 34
ZHX2 zinc fingers and homeoboxes 2 downregulation PFC BD 35
ZIC1 Zic family member 1
(odd-paired homolog, Drosophila)
downregulation PFC BD 35
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inantly affect the proteome rather than the more stable
genome. It is important to remember that, since every sin-
gle gene determines a multitude of gene products, in order
to understand molecular processes in neuropsychiatricdisorders, it is necessary to unravel signal transduction
pathways and complex interaction networks which affect
proteins, not only DNA and mRNA. Proteomics utilizes
high-throughput mass spectrometric methods for protein
identification that can help to reveal protein expression
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interactions [39]. On the other hand, the use of proteomics
to examine the modifications in protein expression also en-
ables the identification of the new candidate genes for
suicide. Thanks to an international initiative, the Human
Proteome Organization (HUPO) was founded. HUPO is
an international scientific organization representing and
promoting proteomics through international cooperation
and collaborations. Through ensuring public availability of
collected data, HUPO supports the development of prote-
omics and fosters further research (www.HUPO.org). The
field of proteomic studies of post-mortem brain tissue is
still relatively unexplored. Schlicht et al. [40] used prote-
omic analysis by means of two-dimensional polyacryl-
amide gel electrophoresis (2D- PAGE) to compare protein
patterns in the post-mortem PFC tissues of suicide victims
and controls. They found three proteins, which were
present exclusively in the suicide group. By means of mass
spectrometry, they managed to identify these proteins as a
phosphorylated isoform of glial fibrillary acidic protein
(GFAP), manganese superoxidase dismutase (SOD2) and
α crystallin chain B (CRYAB). GFAP is a component of
glial filaments specific to astrocytes and was found up-
regulated in reactive gliosis, as well as in several neurode-
generative disorders [41]. Interestingly, it is exactly the
phosphorylated form of GFAP that has been implicated in
the pathophysiology of psychiatric disorders [42]. SOD2 is
a major antioxidant enzyme involved in the detoxification
of superoxide radicals. Schlicht and colleagues propose to
interpret their finding of SOD2 in the PFC of suicide sub-
jects as a compensatory mechanism under the conditions
of intensified oxidative stress. This corresponds well with
the reports of elevated levels of this enzyme in different
psychiatric disorders [34,43-45]. On the other hand, a
study by Pae et al. [46] failed to support an association of
manganese superoxide dismutase (one of the antioxidant
enzyme) gene polymorphism (MnSOD: Ala-9Val) with the
development of mood disorders or their clinical parame-
ters in the Korean population. Nevertheless, looking at the
association between the oxidative stress and suicidality
seems to be a new interesting direction of research.
The third protein Schlicht and colleagues found present
only in suicidal victims, CRYAB, belongs to the low mo-
lecular heat shock proteins (small heat shock protein,
sHsp). One of its important roles is the protection of inter-
mediate filaments, such as GFAP in astrocytes, against ag-
gregation and inactivation. The authors conclude that the
expression of these three proteins in the PFC of suicide vic-
tims might indicate a possible existence of an intermitting
component between glial function and suicidal behaviour.
They suggest that the serotonergic system can indeed play
such a role, especially because animal studies showed 5HT-
sensitive astrocytes from 5-HT-depleted regions of rat
brain revealed up-regulation of GFAP synthesis [47]. Thishypothesis is consistent with many reports confirming an
involvement of the serotonergic system in suicide (see
below). Brunner et al. [48] performed proteomic analyses
of the CSF in un-medicated patients with major depressive
disorder with and without a history of suicide attempt.
Two-dimensional gel electrophoresis revealed that suicide
attempters differed from non-attempters in one protein
with an approximate molecular weight of 33 kD and an
isoelectric point of 5.2. The authors concluded that prote-
omic analysis of the CSF could be a promising non
hypothesis-driven screening method for the detection of
new candidate genes in neurobiological suicide research.
Neurotransmitter systems
Serotonergic system
A vast amount of data documents a role of abnormalities in
the serotonergic system in suicidal behaviour. Different ele-
ments of this complex system, including serotonin recep-
tors, serotonin transporter and tryptophan hydroxylase, the
rate-limiting enzyme in the synthesis of serotonin, have
been researched in this respect. Quite understandably, nu-
merous post-mortem studies have also focused on changes
in the serotonergic system.
Serotonin receptors
Out of the 14 known different receptors for serotonin, the
post-mortem studies have mainly focused on 5HT-1A,
5HT-1B, 5HT-1D, 5HT-2A, 5HT-2C, which have been
proposed to play a role in depressive disorder, increased
stress response, anxiety and suicidal behaviour. 5HT-1A
serotonin receptors have been studied using autoradio-
graphic methods and homogenate binding methods with
8-hydroxy-2-(di-n-propyloamino) tetralin (8-OH-DPAT)
as the ligand. Stockmeier and colleagues [49] reported that
the binding of [3H]8-OH-DPAT to serotonin-1A receptors
was significantly increased in the midbrain dorsal raphe of
suicide victims with major depression, as compared with
control subjects. The density of 5HT-1A receptor binding
sites in the PFC was also found increased in nonviolent
suicide victims [50]. This result however conflicts with a
number of other studies focused on the same recep-
tors in the PFC, which showed no changes in this region
[51-53]. However, a more recent study by Stockmeier
et al. [54] has shown that, while there was no difference in
the agonist-binding to 5HT-1A receptors between de-
pressed patients and control subjects, the antagonist-
binding was significantly decreased in outer layers of the
PFC obtained from subjects diagnosed with major depres-
sive disorder, the psychiatric diagnosis most common in
suicide victims. Furthermore, Arango et al. [55] described
differences in density of [3H]8-OH-DPAT binding be-
tween nonviolent suicide victims and control subjects in
Brodmann areas 8 and 9. Interestingly, this different dens-
ity was observed in male suicide victims only. Finally, an
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of the HIP of suicide victims compared to controls was de-
scribed by Joyce and colleagues [56]. However, other studies
reported no differences in hippocampal 5HT-1A receptor
binding [52,53]. Arraz et al. [51] observed a significant de-
crease in the 5HT-1A binding affinity in suicide victims
who died as a result of an overdose of tricyclic antidepres-
sants. They tried to explain this by the higher sensitivity of
this binding site to the acute administration of TCA.
In summary, although the results of studies focusing on
a role of 5HT1A receptors in suicidality are inconsistent,
it appears that there may be an increase in their density in
particular areas of the brain (raphe nuclei, Brodmann area
8 and 9). The serotonin 1B receptor has been suggested to
play a role in suicide, aggression and substance abuse
[57]. New et al. [58] reported an association between the
G861C polymorphism in the coding region of the 5HT-1B
receptor gene and susceptibility to suicide attempts in
Caucasian subjects, while, concordant to the results of
other studies based on mixed population [59,60], no asso-
ciation was observed in the ethnically mixed overall
sample. Another study [61], including two ethnically
homogenous samples of German and Slavic origin, does
not support the involvement of this 5HT-1B receptor
polymorphism in suicide. In the above mentioned study
Arraz et al. [51] looked also at the 5HT-1D serotonin re-
ceptor. A significant decrease in 5HT-1D binding affinity
was found in depressed suicide victims, while the number
of 5HT-1D binding sites showed a significant decrease in
the non-depressed suicide victims. 5HT-2A, another sero-
tonin receptor with a possible role in suicidality, can be la-
beled by several ligands, such as ketaserin, spiperon or
lysergic acid diethyl amide (LSD), none of them com-
pletely specific. The use of nonspecific ligands can explain
inconsistent results of studies focusing on this receptor.
While the results of the first study by Stanley and Mann
[62], showing increased 5HT-2A binding sites in frontal
cortex (FC) of suicide victims, were later confirmed
by further research [63-68], a number of other stud-
ies presented contradictory results with no difference
[51,53,69-72] or, in one case, a decrease [73] in this
receptor binding. In order to eliminate these discrepancies,
Pandey et al. [66] examined both protein and mRNA ex-
pression of 5HT-2A receptors in several regions of the
post-mortem brains of teenage suicide victims. They found
that both protein and mRTA expression levels of these re-
ceptors were significantly increased in the PFC and the
HIP, but not in the nucleus accumbens of suicide victims.
These results were next confirmed by Escriba et al. [74].
Shelton et al. [75] reported 5HT-2A receptor protein ex-
pression in Brodmann area 10 obtained from major depres-
sive disorder subjects, both suicide victims and not, to be
increased in comparison to non-depressive subjects. Re-
garding the 5HT-2C receptor, a regulatory role in mood,appetite and sexual behaviour was suggested [76,77].
Pandey et al. [78] determined the protein and mRNA ex-
pression of 5HT-2C receptors in the PFC Brodmann area
9, the HIP and choroid plexus of suicide victims and nor-
mal controls. They found higher protein expression in the
PFC, but not in other brain regions of suicidal subjects.
On the other hand, there was no significant difference in
the mRNA expression in any of the studied regions. Since
5HT-2C receptor mRNA undergoes post-translational
editing into two different receptor isoforms [79], a possible
involvement of this process in the pathophysiology of sui-
cidal behaviour was also suggested. Gurevich et al. [80]
found that the pre-mRNA editing of the 5HT-2C recep-
tors at the C' site was significantly increased, while the
editing at the D site was decreased, and the C site showed
a trend towards increased editing in the suicide victims
with a history of major depression as compared with con-
trol subjects. Dracheva et al. [81] described the pre-
mRNA editing of the 5HT-2C receptor in subjects with
bipolar disorder or schizophrenia. Those of the subjects
who died by suicide showed differences in editing local-
ized in dorsolateral PFC, which were not present in sub-
jects who died of natural causes. It has been proposed that
5HT2C-receptor-coupled signaling is altered in suicide
victims due to modified G protein-coupling as a result of
mRNA editing [82]. A suggested association between sui-
cide and the single nucleotide polymorphism in the cod-
ing region of the 5HT-2C receptor gene, resulting in
(Cys22Ser) substitution, although most probably causing
functional differences between the two variants [83],
has not been proved [84]. However, a significant asso-
ciation was observed between female suicide victims of
Slovenian origin and the SN polymorphism 68G>C
(Cys23Ser) in 5HT-2C receptor gene [85].
Tryptophan hydroxylase
Tryptophan hydroxylase is the rate limiting enzyme in
the synthesis of serotonin. Post-mortem studies, indicated
a greater density and number of TPH-immunoreactive
(TPH-IR) neurons in the dorsal raphe nucleus [86] and
higher TPH-IR in the dorsal, but not in the median raphe
nucleus, in depressed suicide victims [87]. About ten years
ago, two isoforms of TPH have been identified, TPH1 and
TPH2, of which the latter is expressed primarily in the
brain [88]. The isoforms are encoded by two genes located
on different chromosomes. Haplotype and association
studies of different SNPs suggest the involvement of the
TPH2 gene in suicide. Zill et al. [89] reported a statistically
significant association between the rs1386494 SNP of the
TPH2 gene and suicide. They also found three TPH2
haplotypes which significantly differed in their distri-
bution between suicide completers and control subjects.
In the TPH1 gene in turn, there are two common
polymorphisms on intron 7: A218C and A779C
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band), which are in very high linkage disequilibrium. In
one post-mortem study, the AA genotype was associated
with higher TPH immunoreactivity and lower 5-HT2A
binding in the PFC compared to other genotypes in both
suicides and non-suicides, suggesting a regulatory role of
this enzyme in the functioning of serotonergic system [90].
Serotonin transporter
The serotonin transporter, a target protein for a number
of antidepressant drugs, including SSRIs, has also been a
subject of post-mortem brain studies. Depressed suicides
were shown to present with fewer serotonin transporters
in the PFC (suicide or major depression), hypothalamus
(suicide), occipital cortex (major depression) and brain-
stem (suicide and major depression) [90,91]. Importantly,
this PFC deficit in suicide victims appears localized to the
ventromedial PFC (a brain region involved in willed action
and decision-making), whereas major depression is associ-
ated with lower binding throughout the PFC [92]. On the
other hand, Bligh-Glover et al. [93] showed a significant
increase in [(3)H]paroxetine binding to serotonin trans-
porters in the entire dorsal raphe nucleus, progressing
from rostral-to-caudal levels in both normal control sub-
jects and suicide victims with major depression. At com-
parable rostral-to-caudal levels, there were no significant
differences in serotonin transporters found between de-
pressed suicide victims and normal control subjects in ei-
ther the entire dorsal raphe nucleus or its constituent
subnuclei. One of the proposed causes of lower serotonin
transporter binding in depression and suicide was the
prevalence of a short variant (S allele) of functional promo-
tor polymorphism of the transporter gene (5-HTTLPR).
This theory however has not been confirmed by either
post-mortem [92] or imaging studies [94,95]. Zupanc
et al. [96] reported no association between polymor-
phisms in serotonin transporter gene (5-HTT) (poly-
morphism LPR in promoter and VNTR in the second
intron), as well as in different serotonin receptor genes
(HTR): HTR1A (polymorphism -1019C>G), HTR1B (poly-
morphisms 861G>C and -161A>T), HTR1F (polymorph-
ism -78C>T) and HTR2A (polymorphism -1420C>T), and
completed alcohol-related suicide.
Noradrenergic and dopaminergic system
Adrenergic receptors
Gross-Isseroff [73] and colleagues reported significantly
lower binding to alpha 1-receptors in several brain regions
of the suicide group as compared with matched controls.
The decrease in receptor density was observed in portions
of the PFC, in the temporal cortex (TC) and the caudate
nucleus (CN). An increase in alpha 1-adrenergic binding
in PFC was confirmed by Arango et al. [97]. Meana and
Garcia-Sevilla [98], as well as González et al. [99] showedan increase in the number of alpha 2-adrenoreceptor
agonist binding sites in the HIP and the FC of depressed
suicide victims. Ordway et al. [100] and Ordway [101] de-
scribed the same effect in locus coeruleus (LC), the princi-
pal source of brain norepinephrine. In contrast to those
studies, Gross-Isseroff et al. [102] reported no significant,
region-dependent alterations in the density of alpha 2-
adrenergic receptors in brains of suicide victims as com-
pared to matched controls. Since a few subtypes of
adrenergic receptors were described and specifically
localised in different parts of the brain (alpha1A, alpha1B
and alpha1D as well as alpha2A, alpha2B and alpha2C)
[103,104], post-mortem studies provided a possibility to
establish differences in receptor subtype locations, in their
density and functioning, as well as in their role in
sucidality. According to the study by De Paermentier et al.
[105], who looked at adrenergic receptors in suicide vic-
tims in relation to treatment with antidepressants, the
number of alpha1A- and alpha1D-adrenoceptors did
not differ significantly between antidepressant-free or
antidepressant-treated suicide subjects and controls. In
antidepressant-free suicide subjects, the number of alpha2-
adrenoceptors, however not alpha2A-adrenoceptors in
particular, was significantly higher in the TC. In
antidepressant-treated suicides, significantly lower num-
bers of alpha2-adrenoceptors were found in occipital cor-
tex (OC) and HIP (and for alpha2A-adrenoceptors in the
CN and the amygdala) compared to controls. On the
other hand, Meana et al. [106] found both the density and
affinity of alpha 2A-adrenoceptors in the high-affinity
state to be increased, especially in the FC and the hypo-
thalamus (HTH) of depressed suicides, a finding later con-
firmed by Callado and colleagues [107], who described a
greater proportion of alpha2A-adrenoceptors in the high-
affinity conformation in the FC of depressed suicide vic-
tims. Moreover, González-Maeso et al. [108] described an
increase in alpha 2A- adrenoceptor sensitivity in the FC
of depressed suicide victims. García-Sevilla et al. [109]
reported an up-regulation of alpha 2A-adrenoceptors in
the PFC (Brodmann area 9) of suicide subjects. One study
reported an increase in biding to beta-adrenergic recep-
tors in the PFC and the TC of the suicide victims [110].
Gurguis et al. [111] examined agonist affinity and coupling
efficiency of beta-adrenergic receptors to Gs protein in
the brains of ten suicide victims. They found no differ-
ences in the receptor densities in either the FC or HIP
of suicide victims compared to controls, however, the
preliminary results indicated beta-adrenergic receptors
supercoupling in suicide victims in both brain regions.
Following these findings, Little et al. [112] tested the
hypothesis that the pineal beta-adrenergic binding is
increased in depressed persons committing suicide,
reflecting diminished noradrenergic input. They found no
differences in pineal beta-adrenergic receptors between
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When comparing the density of beta-adrenoceptors with
that of alpha2-adrenoceptors, Sastre et al. [113] found that,
in brains of suicide victims, the ratio between alpha2- and
beta-adrenoceptors (alpha2-full agonist sites/beta-sites) was
greater compared to controls. A genetic study of alpha2A-
adrenoceptors revealed – in concordance to the results of
most autoradiographic and immunolabelling studies – an
increased mRNA expression of the receptor gene in sui-
cide subjects [74]. Sequeira et al. [114] looked at genetic
variations of the alpha 2A-adrenergic receptor gene
(ADRA2A) at four loci, including three in the promoter
region (g-1800t, c-1291 g and the g-261a), and a poten-
tially functional locus, N251K, which leads to an amino
acid change (asparagine to lysine). They found no signifi-
cant differences at the promoter loci in terms of allelic or
genotypic distribution between suicide victims and con-
trols. However, analysis of the functional polymorphism
N251K revealed that the 251 K allele was only present
among suicides, though only in three out of 110 cases.
These results were not replicated either by Martín-
Guerrero et al. [115] or by Fukutake et al. [116], although
the latter study reported a significant association of the
C-1291G SNP in the promoter region of the alpha 2A-
adrenergic receptor gene with suicide in Japanese fe-
males. A link between the rs1018351 SNP in alpha
2B-adrenergic receptor gene and suicidal attempt was also
reported [117]. Since different studies mentioned above
confirm alterations in cortical beta- and alpha-adrenergic
receptor binding, Arango et al. [118] studied specifically
the pigmented neurons of the LC [119], which provide the
noradrenergic innervations to the cerebral cortex. In the
samples from the suicide group, they observed 23% fewer
LC neurons and a 38% lower density of LC neurons when
compared to control samples. This led them to a conclu-
sion that altered brain noradrenergic neurotransmission
in suicide victims may be due to fewer noradrenergic neu-
rons in the LC.
Tyrosine hydroxylase, Catechol-O-methyltransferase
Tyrosine hydroxylase (TH) is the rate-limiting enzyme for
catecholamine synthesis. Ordway and collegaues [100]
found concentration levels of TH in LC to be elevated in
the samples from suicide victims. Persson et al. [120] stud-
ied TH gene expression and observed a non-significant
tendency towards a lower incidence of the TH-KI allele
among suicide subjects compared to controls, although
there was a significant association of the K3 allele in the
subgroup of patients with adjustment disorder and suicide
attempt. In other studies a trend for association [121]
or no association [122] were reported. Biegon and
Fieldust [123] found no difference between suicide
victims and controls in the levels of the dopaminebeta-hydroxylase (DBH, the last enzyme in the synthesis
of neuroepinephrine) immunoreactivity or in the number
of TH immunoreactive cells. Catechol-O-methyltransferase
is an enzyme metabolizing noradrenaline in the synaptic
cleft. COMT has been shown to affect cognition and per-
sonality traits as well as neuronal activation [124,125],
which suggest it can also play a role in the susceptibility to
suicidal behaviour. The COMT gene has a common func-
tional polymorphism, val158met. One post-mortem study
found the Val allele less prevalent, and the heterozygote
Val/Met more common in male suicide victims than in
controls [126].
Dopaminergic system
Although there is not much data on the role of the
dopaminergic system in suicidality, a reduction in the
dopamine turnover (significantly lower concentration of
dihydroxyphenylacetic acid) was observed in the CN, pu-
tamen (P) and nucleus accumbens (NA) in a post-mortem
study of depressed suicide victims [127]. Allard and
Norlén [128] reported no difference in Bmax and Kd of
the [3H]WIN 35,428 ligand binding to dopamine uptake
sites in the CN between the suicide group and controls.
Since dopamine-and-cAMP-regulated neuronal phospho-
protein (32 kDa) (DARPP-32) is expressed in brain regions
receiving dopaminergic projections, including the PFC,
and is implicated in the pathophysiology of schizophrenia,
Feldcamp et al. [129] determined the DARPP-32 gene ex-
pression in suicide victims with schizophrenia. They found
a significant difference in gene expression levels between
schizophrenia patients who died by suicide vs. other
causes of death, as well as the between the schizophrenia
group and controls.
Glutamatergic system
Based on a known adaptation of the NMDA receptor
complex in the rodent cortex in response to chronic
antidepressant treatment, Nowak et al. [130] hypothe-
sized glutamatergic dysfunction could be involved in
psychopathology underlying suicide. Consequently, they
conducted an analysis of the glutamatergic receptors in
post-mortem brain probes. They reported a reduced pro-
portion of high affinity, glycine displaceable [3H]CGP-
39653 binding to glutamate receptors in suicide victims in
comparison to age- and post-mortem interval-matched
controls. In contrast, neither the potency nor the max-
imum efficacy of glycine to inhibit [3H]CGP-39653 bind-
ing was altered in the FC of suicide victims compared
to controls. The potency of glycine to inhibit [3H]5,7-
dichlorokynurenic acid binding to the strychnine-
insensitive glycine receptor or the specific binding of
[3H]5,7-dichlorokynurenic acid did not differ between the
two groups. Likewise, neither basal nor glycine- or
glutamate enhanced non-equilibrium binding of [3H]
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the findings confirm an involvement of the glutamatergic
system in suicidality. To further support this, Nowak et al.
[119] reported a statistically significant decrease in the po-
tency of zinc to inhibit [(3)H]MK-801 binding to NMDA
receptors in the hippocampal but not cortical tissue of sui-
cide subjects. The authors proposed that the alteration in
zinc interaction with NMDA receptors may be involved in
the psychopathology underlying suicide attempts. How-
ever, other studies found no [131] or very little [132]
evidence for a role of NMDA-binding sites in the patho-
physiology of suicide. Freed and collegues [133] measured
the non-NMDA excitatory amino acid receptors by means
of analyzing the [3H]AMPA binding in the FC, the CN,
and the NA of post-mortem human brain tissue samples.
They found a pronounced increase in total AMPA binding
in the CN in subjects that had committed suicide when
compared to matched controls. An up-regulation of the
binding of the AMPA receptor, was also reported in a
group of suicide victims by Noga et al. [134]. Different fac-
tors interacting with the glutamatergic system should also
be taken into account in suicide research. One interesting
example is a study by Kalkman [135]. Based on the fact
that the glycogen synthase kinase 3 (GSK3) inhibitor, lith-
ium, which has a proven effect against suicide, increased
the activity of glutamine synthetase in an animal experi-
ment [136], he proposed that suicide might be prevented
by centrally acting GSK3 inhibitors.
Other neurotransmitter systems
Cheetham et al. [137] studied GABA receptors by quan-
titating benzodiazepine (BZ) binding sites. They reported
the number of BZ binding sites was significantly greater
in the FC of the total group of depressed suicide subjects
compared to controls, but did not differ in the TC. Vinod
and collegues [138], who looked at the brain samples of
subjects with a history of alcohol abuse, found the canna-
binoid CB(1) receptor density in the dorsolateral PFC was
higher in patient with alcohol addiction who committed
suicide then in those who died of other causes. Western
blot analysis confirmed a greater immunoreactivity of the
CB(1) receptor in alcohol dependent suicide victims. The
CB(1) receptor-mediated [(35)S]GTP gamma S binding also
indicated a greater signaling in this group. The same group
reported an upregulation of CB1 receptors and agonist-
stimulated [35S]GTPgammaS binding in the PFC of de-
pressed suicide victims [139].
Table 2 summarizes the findings regarding neurotrans-
mitter systems and suicidality.
Cell-signalling research
Protein kinases A and C
A disturbance in a signal-transduction process from cell
surface receptors to the nucleus was postulated as a oneof the mechanisms underlying suicidal behaviour. As a re-
sult, a possible role of protein kinase A, an enzyme involved
in the adenyl cyclase (AC) signalling pathway, as well as
protein kinase C, a component of the phosphoinositide (PI)
signalling system, were investigated. Protein kinase A
(PKA), activated by cyclic AMP, works by phosphorylisation
of several intracellular proteins and activates certain tran-
scription factors. Two different PKA izoenzymes were
identified, known as PKAI and PKAII, both compromised
of R and C units. The I and II PKA isoenzymes are built
of different R subunits (called RI and RII), each of them
consisting of RIα and RIβ or RIIα and RIIβ subunits
respectively. Furthermore, three C subunits, known as
Cα, Cβ and Cγ, were described. Post-mortem studies
showed 3[H]-cAMP binding and PKA activity to be
significantly decreased in the PFC of suicide victims
[140,141]. Moreover, a decrease in the catalytic activity
of PKA in Brodmann area 9 and the HIP was also ob-
served in suicide subjects [142]. In concordance with this
observation, Dwivedi and colleagues [141] reported the
protein and mRNA expression of PKA subunits RIIβ and
Cβ to be decreased in PFC of suicide subjects when com-
pared with controls. Pandey et al. [143], who looked at the
activity of the PKA subunits in the post-mortem brain of
teenage suicide victims, found a decreased cAMP binding
and PKA activity in the PFC, but not in the HIP. Shelton
and colleagues [75] studied 5-HT (2A) receptor abun-
dance and PKA activity in post-mortem brain tissue speci-
mens from persons with a history of major depression.
They reported an increased 5-HT(2A) receptor abundance
and decreased PKA activity in the depressed sample. 5-
HT(2A) receptor availability was significantly inversely
correlated with PKC activity in controls, but not with PKA
activity in the depressed sample. The authors propose
these abnormalities of 5-HT(2A) receptor abundance may
depend on receptor uncoupling and heterologous regula-
tion by PKA. A study of serotonin 5-HT2A and 5-HT4
binding parameters and their second messengers 1,4,5-in-
ositol triphosphate (IP3) and cyclic adenosyl mono-
phosphate [129] in the FC, HIP, CA and amygdala of
suicide victims by Rosel et al. [72] revealed significantly
higher number of 5-HT4 receptors and higher second
messenger cAMP concentrations in the FC and CN of the
depressed suicide victims as compared with the control
group. Furthermore, significantly increased 5-HT2A bind-
ing sites and IP3 concentrations were noted in the CN of
the suicide group, together with a significantly reduced
number of 5- HT2A binding sites, higher binding affinity
and increased IP3 concentrations in the HIP. Dwivedi
et al. [144] studied Rap-1, one of the major substrates of
protein kinase A, involved in neuroprotection and synap-
tic plasticity, which can be directly activated by cAMP
through exchange proteins (Epac1, Epac2). They found
that Rap-1 activation was significantly reduced in the PFC
Table 2 Neurotransmitter systems and suicide
System element Change Location
SEROTONERGIC Receptors 5HT-1A upregulated RN, FC
5HT-1D downregulated PFC
5HT-2A downregulated PFC, HIP, FPC
5HT-2C upregulated PFC
5-HT4 upregulated FC, HIP, CN, AN
Enzymes TPH upregulated RN
Transporter Serotonin transporter downregulated PFC, RN
NORADRENERGIC Receptors Alpha-1 downregulated PFC, TC, CN
Alpha-2 upregulated in drug-free subjects HIP, FC, LC, HTH
downregulated in antidepressant- treated subjects OC, HIP
Alpha-2A upregulated in drug-free subjects EC, HTH, PEE
downregulated in antidepressanttreated subjects AN, CN
Beta upregulated PFC, TC
Alpha-2 ‘Beta ratio increased G
Enzymes TH upregulated LC
DOPAMINERGIC Dopamine turnover Dihydroxy- phenylacetic
acid concentration
decreased CN, P. NA
GLUTAMATERGIC Receptors NMDA downregulated G
Zinc inhibition decreased HIP
AMPA upregulated CN
GABA-ERGIC Receptors GABA upregulated FC
ENDOCANNABINOID Receptors CB(1) upregulated PFC
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significant reductions in Rap-1 messenger RNA and pro-
tein levels. In contrast, protein level of only Epac-2, but
not Epac-1 was significantly increased in the PFC and the
HIP of these subjects. To further support an involvement
of the AC signalling system in suicidal behaviour, a re-
sponse to the beta(1)-adrenoceptors agonist-stimulated
AC activity was found significantly lower in post-mortem
brain samples from subjects with major depressive
disorder [145].
Protein kinase C is a regulatory enzyme involved in the
modulation of many neuronal and cellular functions, such
as neurotransmitter synthesis and release, regulation of re-
ceptors and ion channels, neuronal excitability, gene ex-
pression, secretion and cell proliferation [146]. The PKC
family has been sub-grouped into three classes, namely
conventional, novel and atypical izoenzymes, which differ
in molecular structure and enzymatic activity [147-149].
Pandley et al. [150] found that the binding of 3[H]phorbol
12,13-dibutyrate by PKC was significantly decreased in
both membrane and cytosol fractions obtained from the
PFC of teenage suicide victims. Both in the PFC and in
the HIP of teenage suicides, the PKC activity was de-
creased, so was the protein expression of conventional
isoenzymes. The decreased activity was reflected bysignificantly decreased mRNA levels for those isoen-
zymes. Choi et al. [151] found expression levels of the
PRKCI gene, encoding atypical iota isoenzyme of the
PKC family, increased in the PFC of suicide victims as com-
pared to non-suicide controls. One of the substrates for
phosphorylation by protein kinase C, myristoylated alanine-
rich C kinase substrate (MARCKS), involved in neurotrans-
mitter release and re-uptake, was postulated to play a role
in mood disorders [152]. According to another study by
Pandey and colleagues [153], protein levels of MARCKS
were significantly increased in the membrane fraction
of the PFC and the HIP obtained from depressed suicide
subjects as compared to normal controls. The PKC-
mediated MARCKS phosphorylisation was also deter-
mined, and found significantly decreased in the membrane
fraction of the PFC and the HIP obtained from both de-
pressed and non-depressed suicide subjects. The authors
suggest a decrease in MARCKS phosphorylisation may be
a common feature of suicide victims, independent of the
psychiatric diagnoses.
Transcription factor CREB
Activation of PKA, as well as PKC, phosphorylates several
transcription factors, which then influence gene expres-
sion. Cyclic AMP response element binding protein
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cated in the pathophysiology of suicide. Odagaki et al.
[154] quantified the level of CREB in the PFC of depressed
suicide victims by Western blotting. They observed a sig-
nificant increase in the levels of CREB, both in total and
phosphorylisated forms in brains of depressed victims
compared to those of control subjects. The increase was
observed specifically in antidepressant-free subjects, but
not in the antidepressant-treated subjects, which sug-
gests the role of cAMP signaling system in the ther-
apy with antidepressants. Young and colleagues [155]
reported increased numbers of phosphorylated CREB
stained cells in several amygdalar nuclei in subjects who
had died by suicide. On the other hand, Dwivedi et al.
[142] reported the protein expression of CREB was sig-
nificantly decreased in the nuclear fractions of both the
PFC and the HIP obtained from suicide victims com-
pared with control subjects. This was reflected by a de-
crease in the mRNA levels of CREB, as well as in the
CRE-DNA binding activity, as measured in the nuclear
fractions of both the PFC and the HIP. In accordance with
these findings, Pandey and colleagues [156] reported a
specific decrease in CRE-DNA binding and the mRNA
as well as protein expression of CREB in the PFC of
teenage suicide victims. However, they did not find any
significant differences in the HIP CREB levels between
teenage suicides and controls.
Cytokines
Cytokines are small cell-signaling protein molecules which
serve as immuno-modulating agents. Changes in the im-
mune system have been suggested to play a role in depres-
sion and suicidality, following observations of a negative
influence of IFN-alpha on patients' mood [157,158], as
well as of altered levels of pro- and anti-inflammatory cy-
tokines in the serum [159-161] or the CSF of depressed
patients [162,163]. What is more, Lindqvist et al. [164]
found IL-6 level in CSF was significantly higher in suicide
attempters than in healthy control subjects. The number
of post-mortem studies focusing on cytokines is limited.
However, Steiner et al. [165] found microgiliosis, one of
the elements of immunological activation of the brain
tissue, to be increased in the post-mortem brains of sui-
cide victims diagnosed with affective disorders and schizo-
phrenia. Tonelli and colleagues [166] described increased
mRNA expression of IL-4 and IL-3 in the orbitofrontal
cortex of female victims of suicide, as well as of IL-13 in
PFC of male suicide victims compared with control sub-
jects. Pandey et al. [167] reported significantly increased
mRNA and protein expression levels of IL-1β, IL-6, and
TNF-α in Brodmann area 10 of teenage suicide victims as
compared with normal control subjects Table 3 summa-
rizes the findings regarding the role of cell-signalling
in suicide.Neural plasticity
Neurotrophic factors
Neurotrophic factors are a family of proteins that in-
duce the survival, development, and functional differ-
entiation of neurons [168], which includes among others
nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), glial cell line-derived neurotrophic factor
(GDNF), its family ligands neurturin (NTN), persephin
(PSP), and artemin (ARTN), neurotrophin-3 (NT-3), and
neurotrophin-4 (NT-4). The expression of BDNF is regu-
lated by CREB through Ca2+ and the cAMP response
element within exon 3 of BDNF. Given that a change in
CREB levels has been shown in the post-mortem brains of
suicide victims (see above), and the treatment with antide-
pressants causes an increase of BDNF in the brain
[169], it has been hypothesized that depression and/or
suicide may be associated with a decreased level of
BDNF. Furthermore, neurotrophic factors have been
discussed in the etiology of several other neuropsychi-
atric disorders such as schizophrenia and dementia
[170,171]. Dwivedi and colleagues [172] determined the
protein and mRNA expression levels of BDNF in the
PFC and the HIP, finding them both to be significantly
decreased in suicide victims compared with controls.
According to Karege et al. [173], the levels of BDNF
and NT-3 in the HIP and PFC of medication-free suicidal
subjects were significantly decreased in comparison with
controls. Interestingly, in suicide victims treated either
with antipsychotic or antidepressant drugs, neurotrophine
levels were not significantly different from those in non-
suicide controls. To further support a role of BDNF in
suicidality, two genetic studies, including a study by
Sarchiapone et al. [174], as well as a meta-analisys by
Zai an colleagues [175], implicate an association be-
tween functional SNP (rs6265) of the BDNF gene and
suicidal behaviour. The SNP results in (Val) to (Met)
substitution in the proBDNF protein at codon 66, and
is thought to be associated with low BDNF levels in
psychiatric disorders. In contrast, de Luca and col-
leagues [176], who analyzed the BDNF Val66Met poly-
morphism in suicide completers and the parent-of origin
effect (POE) in suicide attempters, found no evidence for
allelic imbalance or POE of BDNF for suicidal behaviour.
Dwivedi et al. [172] measured the protein and mRNA ex-
pression of the TrkB receptor, a member of a family of
tyrosine kinases with the highest affinity to the binding of
BDNF. Out of the two known isoforms, the protein and
mRNA expression levels of the full-length the TrkB recep-
tors, but not their truncated isoform, were found signifi-
cantly decreased in the PFC and in the HIP of suicide
subjects. Ernst and colleagues [177] looked at a truncated
splice variant of the TrkB (TrkB.T1), the only isoform
expressed in astrocytes under normal conditions. They
found that 10 out of 28 examined brain probes from
Table 3 Cell-signalling in suicide
System element Change Location
Adenylate cyclase Protein kinase A Enzyme activity decreased PFC, HIP
Enzyme subunits RIl, C3 levels decreased PFC, adult suicides
Enzyme subunits Rkt,
R113 levels
decreased PFC, teenage suicides
Enzyme substrate Rap- 1 reduced activation PFC, HIP
Second messenger cAMP level increased PC, CN
cAMP effector Epac-2 level increased PFC, HIP
CREB level decreased PFC, HIP
increased PFC, antidepressants-free
subjects
increased density of CREB
stained cells
AN
Phospholipase C Protein kinase C Enzyme activity decreased PFC, HIP, teenage suicides
Enzyme substrate MARCKS increased concentration,
decreased phosphorylation
PFC, HIP
Second messenger IP3 level increased HIP, CN
Cytokines Interleukins IL-1β level increased FC, teenage suicide
IL-3 level increased PC, female suicides
IL-4 level increased FC, female suicides
IL-6 level increased PC, teenage suicide
IL-13 level increased PC, male suicides
TNF-Family TNF-α level increased PC, teenage suicide
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TrkB.T1 in the Brodmann areas 8 and 9, a result not
accounted for by substance abuse comorbidity or by re-
duction in astrocyte number. Moreover, it was found that
the methylation of 2 CpG dinucleotides, sites 2 and 5
of the TrkB promoter, is associated with the decreased
expression of TrkB.T1.
The levels of the whole blood glial cell line-derived
neurotrophic factor (GDNF) has been shown to be de-
creased in remitted patients with mood disorders [178]
and one post-mortem study showed an increase in GDNF
concentration in the PC of patients with depressive dis-
order [44], therefore suggesting its involvement in the
pathophysiology of mood disorders and suicidality. Fur-
thermore, both human and animal model have shown that
different antidepressants cause an acute activation of
protein tyrosine kinase (PTK) and extracellular signal-
regulated kinase (ERK), leading to the activation of CREB
and resulting in an increase of the GDNF production
[179-181]. Otsuki et al. [182] used qRT-PCR in peripheral
blood cells of patients with major depressive and bipolar
disorders to measure the expression levels of mRNAs of
different neurotrophic factors. They reported a reduced
expression of GDNF, ARTN, and NT-3 mRNAs in pa-
tients with current major depressive disorder. Altered ex-
pressions of these mRNAs were found neither in remitted
patients with depressive disorder, nor in bipolar patients.Polyamins
Polyamins, including putrescine, spermidine and sperm-
ine, are low molecular weight aliphatic amines involved in
cell proliferation, apoptosis, immunity and oxidative stress
response [183-185]. Changes in the expression of the poly-
amines and their metabolic enzymes have been postulated
in different mental disorders, including suicidal behaviour
[186]. Alterations in the expression of polyamine-related
genes were identified using post-mortem brain tissue
from suicide completers. Sequiera et al. [187] looked
at the spermine/spermidine N(1)- acetyltransferase gene
(SSAT), encoding the rate-limiting enzyme in the catab-
olism of polyamines. They found that an allele of a sin-
gle nucleotide polymorphism (SNP) rs6526342 showed
higher frequency among suicide cases. The authors sug-
gest this SNP allele, located in the SSAT polyamine- re-
sponsive element regulatory region (SSAT342A/C), which
demonstrates a significant effect on SSAT brain expression
levels, may increase the predisposition to suicide. To fur-
ther support this, Fiori et al. [188] showed that suicide
completers who possessed the haplotype containing the
risk allele for the very same SNP (rs6526342) demon-
strated decreased SAT1 expression in Brodmann areas 4,
8/9 and 11. They also identified three other polymor-
phisms - an insertion/deletion (rs6151267), and two SNPs
(rs6526342 and rs928931) - located in the promoter region
of SAT1, which were found to be involved in the
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thors, might thus provide a mechanism for the decreased
SAT1 expression observed in suicide completers. A re-
duction in spermine/spermidine N(1)-acetyltransferase
gene expression in cortical regions of individuals who have
died by suicide was confirmed by Klempan et al. [189] and
Guipponi et al. [190]. The latter study does not support a
role of the rs6526342 SNP in suicide, but highlights the
importance of epigenetic factors influencing the level
of SAT1 expression, a conclusion drawn also by Fiori
and Turecki [191]. Global gene expression profiling of
the polyamine system in suicide completers by Fiori and
colleagues [192] identified 14 genes displaying differential
expression. These included spermidine/spermine N1-
acetyltransferase, spermine oxidase, spermine synthase,
S-adenosylmethionine decarboxylase, ornithine decarboxyl-
ase antizymes 1 and 2, arginase II, aldehyde dehydrogenase
3 family, member A2, brain creatine kinase, mitochondrial
creatine kinase 1, glycine amidinotransferase, glutamic-
oxaloacetic transaminase 1, and arginyl-tRNA synthetase-
like genes. Since many of these genes displayed altered
expression across several brain regions, the authors con-
cluded that a dysregulated polyamine metabolism is a
widespread phenomenon in the brains of suicide com-
pleters. In another study, Fiori et al. [193] genotyped 1255
French-Canadian individuals for the 63 polymorphisms,
spread across 1074 four polyaminergic genes. The group
was followed-up longitudinally for 22 years. The authors
found an association between suicide attempts and poly-
morphisms in SAT1 and the OATL1 genes. Additionally,
different genetic variants of SAT1 were also associated
with anxiety and mood disorders, conditions linked to sui-
cidal behaviour. Taking into consideration a considerable
amount of evidence linking changes in the polyamine
metabolism with suicide, Chen et al. [194] hypothesised
levels of spermine, spermidine and putrescine would be
different in the brains of suicide victims. To this end,
they used a GC-MS method developed specifically for
the measurement of spermidine and putrescine levels
in post-mortem brain tissue [195], to compare the
probes derived from suicide completers and controls.Table 4 Changes in neural plasticity in suicide
System element
Neurotrophic factors Neurotrophins BDNF level
NT-3 level




Spermidine levelsIn correlation with the conclusions drawn from the previ-
ous genetic studies, both putrescine and spermidine levels
were found significantly elevated in the brain of suicide
victims with major depression.
Table 4 gives an overview of the changes in neural
plasticity observed in suicide victims.
Neuroendocrinology
Abnormalities in HPA axis have been postulated both in
mood disorders and suicide. On the one hand, most pa-
tients with depression have been shown to present with
hypercortisolemia both in plasma and CSF, increased corti-
sol response to adrenocorticotropic hormone (ACTH) and
a deficient feedback mechanism, reflected in an abnor-
mal dexamethasone suppression test [11] as well as by
enlarged pituitary and adrenal glands [196-198]. On the
other hand, a large amount of evidence linking HPA axis
dysfunction to suicidality has been published to date.
Yerevanian et al. [199] found that DST non-supressors
with unipolar depression were significantly more likely
to commit suicide than DST suppressors. Similar results
were reported by Coryell and Schlesser [200] in a 15-
years long follow-up study of patients with major de-
pressive disorder or a depressed type of schizoaffective
disorder. As for suicide attempts, some studies report an
association with DST non-suppression [201,202], while
others do not [203,204]. This suggests HPA axis distur-
bances may be more strongly related to suicide comple-
tion rather than just attempts. Thus, studying the
elements of this axis in brain probes from suicide sub-
jects is another interesting area. Raadsheer et al. [205]
reported that the mean total number of CRH-expressing
neurons and of CRH neurons co-expressing AVP in
hypothalamic paraventricular nucleus (PVN) was sig-
nificantly higher in depressed subjects than in the
control group. Merali et al. [206,207] found CRH-
immunoreactivity levels among suicides were elevated
in the LC and in frontopolar, dorsolateral prefrontal
(DMPFC) and ventromedial prefrontal cortices, but re-
duced at the dorsovagal complex (DVC). Austin et al.
[208] hypothesized that CRH levels in suicide victimsChange Location
decreased PFC, HIP,antidepressants-
free subjects
decreased PFC, HIP, antidepressants-
free subjects
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brainstem regions. They next tested this with help of
radioimmuno-cytochemistry, using primary antiserum to
CRH and a ([125])I-IgG secondary antibody. They reported
an increased level of CRH-immunoreactivity in the LC, in
the median raphe and in the caudal dorsal raphe of
depressed suicide subjects compared to controls. In condi-
tions of chronic hypersecretion of CRH, due to down-
regulation, a reduced number of CRF receptor binding sites
should be present. Accordingly, Nemeroff and colleagues
[209] described a marked reduction in the number of
CRF binding sites in the FC of suicide victims compared
with controls. Subsequently, the mRNA levels of CRH1,
but not CRH2 receptors for corticotropin were found
decreased in suicide brains [206]. What is more, a shift
in CRH1:CRH2 mRNA ratio was also reported in pituit-
aries of suicide subjects [210]. The feedback regulation of
the HPA axis by glucocorticosteroids is mediated through
two intracellular receptors, known as mineralocorticoid
(MRs) and glucocorticoid (GRs) receptors. GRs, which are
believed to play an important role in the regulation of stress
response, have been studied in the peripheral tissues of de-
pressed patients [211], who present with a reduced GRs
function sometimes referred to as GR resistance, as well as
in post-mortem brains of patients with different psychiatric
disorders [212,213], which show decreased levels of GRs in
comparison to normal controls. The above described find-
ings indicate that there is a need to also examine a possible
role of GRs in the pathology of suicide. To date, one study
by Lopez and colleagues [214] focused on the localization
of glucocorticoid receptor (GR) mRNA and pro-
opiomelanocortin (POMC) mRNA in anterior pituitaries of
suicide subjects. The analysis of the corticotrophic cell
clumps showed that the suicide victims had a higher
POMC mRNA density per cell and a larger corticotrophic
cell size than controls, however no differences in GR
mRNA were detected between the two groups. McGowan
et al. [215] reported that the expression of total glucocortic-
oid receptor mRNA was significantly reduced in suicide
victims with a history of childhood abuse when compared
to suicide victims who did not suffer childhood abuse or to
controls. Supriyanto et al. [216] tested a possible association




Receptors CRH-receptors receptor d
CRH1-receptor mRNA level decreased
CRH1/CRH2receptor ratio decreasedreceptor (NR3C1), the mineralocorticoid receptor
(NR3C2), and the FK506 binding protein 5 (FKBP5) genes,
all of them involved in HPA axis regulation. The authors
found that the distributions of TT, TC, and GT haplotypes
of the FKBP5 gene (comprised of rs3800373 and
rs1360780) in completed suicide and control groups were
significantly different. Since the FK506 binding protein 5
interacts functionally with mature corticoid receptor
hetero-complexes, this confirms a crucial role of the HPA
axis in suicidality. However, no significant differences in
genotypic distribution of any single SNP in the three genes
in question were observed between the individuals who
completed suicide and control groups Table 5.
Discussion
Limitations
Post-mortem studies on brain tissue have a number of
limitations. One of them is the relatively short period of
time, within which the samples should be collected. For
example, the levels of dihydropyrimidinase-related
protein-2 were found to decrease within 6 h after death
[217]. Thus, the post-mortem interval should ideally not
exceed 6 hours, which sometimes can be very hard to
achieve. Another problem is the small sample size, which
significantly limits the possibility to generate data fit for
detailed statistical analysis, especially regarding genetics.
Only further improvement in brain collection programs
can help to confirm the results of previous pilot studies
based on small groups of subjects. The issue is further
complicated by an considerable overlap between psychi-
atric disorders, all of which might alone be associated with
certain neurobiological abnormalities, and suicide. With
the limited availability of post-mortem samples from psy-
chiatric patients who died of natural causes, it is very diffi-
cult to examine if the neurobiological abnormalities in the
post-mortem brains are related to suicidality or rather to
the psychiatric diagnoses. Hence, there is a need for com-
parison studies of samples obtained from suicide victims
with a particular diagnosis, and those taken from subjects
with exactly the same diagnosis, who died of natural
causes. Another important problem is the influence of
pharmacological and other therapies used in psychiatric
patients on brain biology. Thus, it is difficult to distinguishChange Location




G CRH1-receptor mRNA level
PIT CRH1/CRH2receptor ratio
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suicidality and not related to comorbid psychiatric disor-
ders or caused by psychiatric treatment. Last but not least,
the role of obtaining a very detailed psychological history
should never be underestimated. The use of validated
methods to reconstruct psychiatric history by means of ex-
tensive proxy-based interviews [218] is indispensable in
order to eliminate possible confounding variables influen-
cing the results, such as the history of childhood abuse,
other trauma, personality disorders, but also somatic
diagnoses.Future possibilities
Post-mortem studies of suicidality provide many possibilities
for widening our knowledge of the underlying neuropathol-
ogy and of the influence of medication and substance abuse,
as well as for constructing and testing different clinical hy-
potheses. Several interesting new research directions of
post-mortem studies are conceivable for the future, includ-
ing innovative genetic and epigenetic studies with the use of
new data bases and new brain collection programs. Another
unique possibility is the comparison of neurobiological fac-
tors characteristic for suicide in the samples representing
particular psychiatric disorders, as described above. The
same goes for differentiating between neurobiological abnor-
malities related to suicidal behaviour and those associated
with completed suicide. Another interesting possibility
is the description of the effects of different psychiatric
drugs, their actions on genes expression, protein levels and
neuro-receptors, and their efficacy in preventing suicide.
Last but not least, the impact of chronic or acute substance
intoxication on the brain neurobiology and its influence
on the suicide risk could also be further researched in
post-mortem studies.Conclusions
Studies on post-mortem brain tissue provide numerous
possibilities for a deeper insight into the neurobiology of
different psychiatric disorders, including suicidal behav-
iour. With new methods being now introduced to im-
prove the reliability of results, genetic information being
openly available for analyses and comparisons and the
brain tissue banks being founded and expanded, the
post-mortem studies are likely to grow in number and
further develop in future.
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